期刊介绍：

S. Kjeldsen explains the rational behind the EuroIntervention supplement – “Hyper - tension is the most important risk factor for cardiovascular (CV) disease. According to WHO data, approximately 20% of global mortality is directly related to hypertension, this is quite alarming when one considers that soon 1.5 billion hypertension people will develop hypertension. Approximately 10% of this group have so-called treatment resistant hypertension (TRH) in the sense that their blood pressure is still not under control despite the intake of maximally tolerated doses of at least three antihypertensive drugs including a diuretic. These are the hypertensive patients with the highest risk of having CV complications. These patients need a thorough work up for secondary hypertension, spurious hypertension and poor drug adherence, however if diagnosis is confirmed, new treatment modalities like renal sympathetic denervation (RDN) and baroreceptor activating therapy (BAT) are now available. EuroIntervention is today publishing with a supplement devoted to TRH which covers most aspects including the work-up program, medical treatment and methods and various devices for RDN and BAT. The special issue of EuroIntervention updates the reader in all aspects of this multidisciplinary field of preventive and interventional medicine. Together with Felix and Joost, I would like to thank the authors, from both the hypertensive and interventional fields for theircontributions to what I believe for the readers is a true reference publication in this dynamic field.”